Factors influencing the overestimation of plasma vancomycin concentrations measured by the abbott TDx technique

Therapeutic Drug Monitoring

Volumn 27, Issue 1, 2005, Pages 58-62

  Iwamoto, Takuya ^a   Kagawa, Yoshiyuki ^a   Kojima, Michio ^a  

^a MIE UNIVERSITY   (Japan)

Author keywords

Bilirubin; Blood concentration; Eksborg plot; TDx assay; Vancomycin

Indexed keywords

BILIRUBIN; DRUG METABOLITE; VANCOMYCIN;

ACCURACY; ADOLESCENT; ADULT; AGED; ARTICLE; BILIRUBIN BLOOD LEVEL; BLOOD SAMPLING; CHILD; CONTROLLED STUDY; CORRELATION COEFFICIENT; DEMOGRAPHY; DRUG BLOOD LEVEL; DRUG DETERMINATION; DRUG MONITORING; FEMALE; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; HUMAN; INTERMETHOD COMPARISON; KIDNEY FUNCTION; LIVER FUNCTION; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; REGRESSION ANALYSIS;

BILIRUBIN; BLOOD CHEMICAL ANALYSIS; CHROMATOGRAPHY, HIGH PRESSURE LIQUID; CREATININE; DRUG ADMINISTRATION SCHEDULE; FEMALE; FLUORESCENCE POLARIZATION; HUMANS; MALE; MIDDLE AGED; REPRODUCIBILITY OF RESULTS; TIME FACTORS; VANCOMYCIN;

EID: 13244250955     PISSN: 01634356     EISSN: None     Source Type: Journal    
DOI: 10.1097/00007691-200502000-00012     Document Type: Article

References (24)

1. Sorrell TC, Packham DR, Shanker S, et al. Vancomycin therapy for methicillin-resistant Staphylococcus aureus. Ann Intern Med. 1982;97:344-350.
2. Farber BF, Moellering RC Jr. Retrospective study of the toxicity of preparations of vancomycin from 1974 to 1981. Antimicrob Agents Chemother. 1983;23:138-141.
3. Rybak MJ, Albrecht LM, Boike SC, et al. Nephrotoxicity of vancomycin, alone and with an aminoglycoside. J Antimicrob Chemother. 1990;25:679-687.
4. Moellering RC Jr, Krogstad DJ, Greenblatt DJ. Pharmacokinetics of vancomycin in normal subjects and in patients with reduced renal function. Rev Infect Dis. 1981;3:230-235.
5. Cimino MA, Rotstein C, Slaughter RL, et al. Relationship of serum antibiotic concentrations to nephrotoxicity in cancer patients receiving concurrent aminoglycoside and vancomycin therapy. Am J Med. 1987; 83:1091-1097.
6. Sorrell TC, Collignon PJ. A prospective study of adverse reactions associated with vancomycin therapy. J Antimicrob Chemother. 1985;16:235-241.
7. Mellor JA, Kingdom J, Cafferkey M, et al. Vancomycin toxicity: a prospective study. J Antimicrob Chemother. 1985;15:773-780.
8. Downs NJ, Neihart RE, Dolezal JM, et al. Mild nephrotoxicity associated with vancomycin use. Arch Intern Med. 1989;149:1777-1781.
9. Cantu TG, Yamanaka-Yuen NA, Lietman PS. Serum vancomycin concentrations: reappraisal of their clinical value. Clin Infect Dis. 1994;18:533-543.
10. Iwamoto T, Kagawa Y, Kojima M. Clinical efficacy of therapeutic drug monitoring in patients receiving vancomycin. Biol Pharm Bull. 2003;26:876-879.
11. Morse GD, Nairn DK, Bertino JS Jr, et al. Overestimation of vancomycin concentrations utilizing fluorescence polarization immunoassay in patients on peritoneal dialysis. Ther Drug Monit. 1987;9:212-215.
12. Anne L, Hu M, Chan K, et al. Potential problem with fluorescence polarization immunoassay cross-reactivity to vancomycin degradation product CDP-1: its detection in sera of renally impaired patients. Ther Drug Monit. 1989;11:585-591.
13. 12 internal standard: comparison of high-performance liquid chromatography, emit, and fluorescence polarization immunoassay methods. Ther Drug Monit. 1990;12:562-569.
14. Morishige H, Shuto H, Ieiri I, et al. Instability of standard calibrators may be involved in overestimating vancomycin concentrations determined by fluorescence polarization immunoassay. Ther Drug Monit. 1996;18:80-85.
15. Eksborg S. Evaluation of method-comparison data. Clin Chem. 1981;27:1311-1312.
16. White LO, Holt HA, Reeves DS, et al. Evaluation of Innofluor fluorescence polarization immunoassay kits for the determination of serum concentrations of gentamicin, tobramycin, amikacin and vancomycin. J Antimicrob Chemother. 1997;39:355-361.
17. Ristuccia PA, Ristuccia AM, Bidanset JH, et al. Comparison of bioassay, high-performance liquid chromatography, and fluorescence polarization immunoassay for quantitative determination of vancomycin in serum. Ther Drug Monit. 1984;6:238-242.
18. Filburn BH, Shull VH, Tempera YM, et al. Evaluation of an automated fluorescence polarization immunoassay for vancomycin. Antimicrob Agents Chemother. 1983;24:216-220.
19. Farin D, Piva GA, Gozlan I, et al. A modified HPLC method for the determination of vancomycin in plasma and tissues and comparison to FPIA (TDX). J Pharm Biomed Anal. 1998;18:367-372.
20. Brown N, Ho DH, Fong KL, et al. Effects of hepatic function on vancomycin clinical pharmacology. Antimicrob Agents Chemother. 1983; 23:603-609.
21. Marti R, Rosell M, Pou L, et al. Influence of biochemical parameters of liver function on vancomycin pharmacokinetics. Pharmacol Toxicol. 1996;79:55-59.
22. Freeman CD, Quintiliani R, Nightingale CH. Vancomycin therapeutic drug monitoring: is it necessary? Ann Pharmacother. 1993;27:594-598.
23. Chambers HF. Antimicrobial agents: protein synthesis inhibitors and miscellaneous antibacterial agents. In: Hardman JG, Limbird LE, Gilman AG, eds. Goodman and Gilman's The Pharmacological Basis of Therapeutics, 10th ed. New York: McGraw-Hill, 2001:1262-1264.
24. Levine DP, Fromm BS, Reddy BR. Slow response to vancomycin or vancomycin plus rifampin in methicillin-resistant Staphylococcus aureus endocarditis. Ann Intern Med. 1991;115:674-680.